Stocktoria
Kura Oncology, Inc. KURA
Kura Oncology, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $67.5M | $53.9M | $0 | — | — | — | — | — | — | — |
| R&D expense | $251.1M | $170.0M | $115.2M | $92.8M | $84.7M | $60.4M | $47.8M | $46.8M | $26.4M | — |
| SG&A expense | $120.0M | $77.1M | $50.6M | — | — | — | — | — | — | — |
| Operating income | -$303.6M | -$193.2M | -$165.8M | -$139.9M | — | — | — | — | — | — |
| Interest expense | — | — | $1.5M | $229,000 | $414,000 | $578,000 | $580,000 | $970,000 | $888,000 | $577,000 |
| Income tax | $297,000 | $2.0M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$278.7M | -$174.0M | -$152.6M | -$135.8M | -$130.5M | -$89.6M | -$63.1M | -$60.4M | -$35.4M | -$27.6M |
| EPS (diluted) | $-3.18 | $-2.02 | $-2.08 | $-2.03 | $-1.97 | $-1.69 | — | — | — | — |
| Operating cash flow | -$64.1M | $134.3M | -$124.8M | -$110.1M | -$104.6M | -$69.8M | -$54.8M | -$48.7M | -$28.4M | -$25.3M |
| Free cash flow | -$70.7M | $133.8M | -$125.0M | -$110.7M | -$105.7M | -$72.0M | — | — | — | — |
| Cash & equivalents | $149.1M | $224.5M | $37.3M | $51.8M | $90.7M | $325.5M | $26.1M | $16.1M | $11.4M | $9.7M |
| Inventory | $413,000 | $0 | — | — | — | — | — | — | — | — |
| Total assets | $738.4M | $760.2M | $448.9M | $456.3M | $534.1M | $647.2M | $242.0M | $182.4M | $95.9M | $69.8M |
| Total liabilities | $564.2M | $346.5M | $51.7M | $36.0M | $27.4M | $36.3M | $23.2M | $21.4M | $16.0M | $12.9M |
| Shareholders' equity | $174.1M | $413.6M | $397.3M | $420.3M | $506.6M | $610.9M | $218.8M | $161.0M | $79.9M | $56.9M |
Growth · year-over-year
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +25.2% | — | — | — | — | — | — | — | — | — |
| Free cash flow growth | -152.8% | — | — | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.